Physician Views Preview: Keytruda hits its mark in early-stage TNBC

Merck & Co.’s PD-1 inhibitor Keytruda is already approved in the US for use in combination with chemotherapy to treat PD-L1 positive, metastatic triple-negative breast cancer (TNBC).

Last week, new data was presented showing that the same regimen reduced the risk of event-free survival (EFS) events by 37% versus chemotherapy plus placebo in patients with high-risk, early-stage TNBC. Merck noted that "this is the first time an anti-PD-(L)1 therapy has demonstrated a statistically significant EFS result as combined neoadjuvant and adjuvant therapy for these patients."

We are snap-polling oncologists who regularly treat TNBC patients to gauge reaction to these results, which are from Merck’s Keynote-522 clinical study. Specifically we are asking them…

  • If approved would they plan to use Keytruda/chemotherapy to treat early-stage TNBC before overall survival data matures
  • Would they consider these data to be practice-changing
  • What percentage of high risk early-stage TNBC patients they would consider to be candidates for treatment with Keytruda/chemotherapy based on these data
  • What percentage of high risk early-stage TNBC patients they would consider to be candidates for treatment with Keytruda/chemotherapy if overall survival data is statistically significant in favour of the immunotherapy-based combination.

Results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

To read more Physician Views articles, click here.